Published in Cancer Res on November 01, 1978
Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol (1993) 2.29
The current state of preclinical prostate cancer animal models. Prostate (2008) 1.68
Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone. Br J Cancer (1997) 1.11
Modulation of blood flow, hypoxia, and vascular function in orthotopic prostate tumors during exercise. J Natl Cancer Inst (2014) 1.02
Impact of stroma on the growth, microcirculation, and metabolism of experimental prostate tumors. Neoplasia (2007) 0.97
Analysis of changes in rat prostate carcinoma following hormone deprivation. Am J Pathol (1987) 0.87
Characterization of a rat model of metastatic prostate cancer bone pain. J Pain Res (2010) 0.84
Effects of exercise training on tumor hypoxia and vascular function in the rodent preclinical orthotopic prostate cancer model. J Appl Physiol (1985) (2013) 0.82
The epithelial origin of a stromal cell population in adenocarcinoma of the rat prostate. Am J Pathol (1987) 0.78
EMT and MET: necessary or permissive for metastasis? Mol Oncol (2017) 0.77
Developing oxygen-enhanced magnetic resonance imaging as a prognostic biomarker of radiation response. Cancer Lett (2016) 0.76
FGFR3-expressing smooth muscle-like stromal cells differentiate in response to FGFR2IIIb-expressing prostate tumor cells and delay tumor progression. In Vitro Cell Dev Biol Anim (2011) 0.76
Measurement of hypoxia-related parameters in three sublines of a rat prostate carcinoma using dynamic (18)F-FMISO-Pet-Ct and quantitative histology. Am J Nucl Med Mol Imaging (2015) 0.75
Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development. World J Urol (2000) 0.75
High dose rate radiation treatment of experimental intramuscular prostate carcinoma. Int J Radiat Biol (2009) 0.75
Blood flow responses to mild-intensity exercise in ectopic vs. orthotopic prostate tumors; dependence upon host tissue hemodynamics and vascular reactivity. J Appl Physiol (1985) (2016) 0.75
Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studies. J Cancer Res Clin Oncol (2006) 0.75
The development of human benign prostatic hyperplasia with age. J Urol (1984) 8.29
Identification of a nuclear protein matrix. Biochem Biophys Res Commun (1974) 5.41
Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene. Nature (1993) 4.81
Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res (1997) 4.05
KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science (1995) 3.97
A fixed site of DNA replication in eucaryotic cells. Cell (1980) 3.78
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res (1999) 3.58
Nuclear protein matrix: association with newly synthesized DNA. Science (1975) 3.27
Nuclear matrix. Isolation and characterization of a framework structure from rat liver nuclei. J Cell Biol (1977) 3.26
Supercoiled loops and eucaryotic DNA replicaton. Cell (1980) 3.24
Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. J Natl Cancer Inst (1998) 3.13
Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst (1995) 2.70
Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate (1987) 2.70
Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res (1999) 2.55
Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology (1988) 2.38
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res (1993) 2.22
Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl (1989) 2.12
Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res (1991) 2.08
The role of the nuclear matrix in the organization and function of DNA. Annu Rev Biophys Biophys Chem (1986) 2.07
Expression of the prostate-specific membrane antigen. Cancer Res (1994) 2.06
DNA packaging and organization in mammalian spermatozoa: comparison with somatic cells. Biol Reprod (1991) 1.99
Considerations in the isolation of rat liver nuclear matrix, nuclear envelope, and pore complex lamina. Exp Cell Res (1981) 1.99
Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate (1996) 1.91
Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res (1996) 1.88
Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res (1996) 1.87
Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res (1990) 1.82
Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol (1989) 1.82
Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res (1981) 1.80
Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia (1999) 1.74
Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res (1995) 1.68
The prostate: an increasing medical problem. Prostate (1990) 1.67
The specific binding of estrogens and androgens to the nuclear matrix of sex hormone responsive tissues. J Biol Chem (1980) 1.66
Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate (1986) 1.65
Stem cell features of benign and malignant prostate epithelial cells. J Urol (1998) 1.62
Activation of programmed cell death by recombinant human tumor necrosis factor plus topoisomerase II-targeted drugs in L929 tumor cells. J Natl Cancer Inst (1991) 1.57
Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am J Pathol (1998) 1.57
Fourier analysis of cell motility: correlation of motility with metastatic potential. Proc Natl Acad Sci U S A (1989) 1.55
Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res (2001) 1.54
The epidemiology of prostate cancer in Jamaica. J Urol (1998) 1.53
The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res (1994) 1.53
Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer (2002) 1.53
Future prospects in prostate cancer. Prostate (1999) 1.53
Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res (1997) 1.51
Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res (1996) 1.50
Intravenous versus epidural administration of hydromorphone. Effects on analgesia and recovery after radical retropubic prostatectomy. Anesthesiology (1995) 1.46
Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res (1995) 1.43
Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ (2001) 1.43
Effects of garlic thioallyl derivatives on growth, glutathione concentration, and polyamine formation of human prostate carcinoma cells in culture. Am J Clin Nutr (1997) 1.43
A structural analysis of the role of the nuclear matrix and DNA loops in the organization of the nucleus and chromosome. J Cell Sci Suppl (1984) 1.43
Polymerization of deoxyribonucleotides in relation to androgen-induced prostatic growth. Arch Biochem Biophys (1968) 1.43
Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. Urology (2001) 1.41
The nuclear protein matrix: isolation, structure, and functions. Adv Enzyme Regul (1976) 1.41
A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? Crit Rev Immunol (2001) 1.39
Interaction between tetraethylthiuram disulfide and the sulfhydryl groups of D-amino acid oxidase and of hemoglobin. J Biol Chem (1966) 1.38
Antagonistic effect of androgen on prostatic cell death. Prostate (1984) 1.36
Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm Genome (2001) 1.36
Identification of nuclear matrix proteins in the cancer and normal rat prostate. Cancer Res (1991) 1.35
Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res (1994) 1.33
Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res (1997) 1.32
Clinical evidence for and implications of the multistep development of prostate cancer. J Urol (1990) 1.32
Early cell motility changes associated with an increase in metastatic ability in rat prostatic cancer cells transfected with the v-Harvey-ras oncogene. Cancer Res (1988) 1.32
The role of androgens and estrogens in the pathogenesis of experimental nonbacterial prostatitis. J Urol (1988) 1.32
Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cells. Nature (1986) 1.31
Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc Natl Acad Sci U S A (1993) 1.29
Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res (1998) 1.28
Nuclear-cytoskeletal interactions: evidence for physical connections between the nucleus and cell periphery and their alteration by transformation. J Cell Biochem (1992) 1.27
Correlation of nuclear morphometry with progression of breast cancer. Cancer (1991) 1.26
CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res (1997) 1.25
Prostate-specific membrane antigen. Prostate (1997) 1.25
Cancer as a disease of DNA organization and dynamic cell structure. Cancer Res (1989) 1.24
Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res (1992) 1.23
The relationship of the nuclear matrix to cellular structure and function. Adv Enzyme Regul (1978) 1.23
Genomic organization of the human KAI1 metastasis-suppressor gene. Genomics (1997) 1.23
Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Res (1989) 1.22
Activation of a Ca2+-Mg2+-dependent endonuclease as an early event in castration-induced prostatic cell death. Prostate (1988) 1.22
Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. Urology (2001) 1.22
Rational basis for Trk inhibition therapy for prostate cancer. Prostate (2000) 1.22
Total prostatectomy for clinically localized prostatic cancer: long-term results. J Urol (1989) 1.21
Comparison of spontaneous and experimentally induced canine prostatic hyperplasia. J Clin Invest (1979) 1.20
Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers. Oncogene (2011) 1.20
Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res (1997) 1.20
A sensitive radioassay for sulfhydryl groups with tetraethylthiuram disulfide. J Biol Chem (1966) 1.20
Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res (1999) 1.19
Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells. Cancer Res (1994) 1.19
New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia. Urology (1999) 1.18
Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate (2001) 1.17
Epidemiologic evidence regarding predisposing factors to prostate cancer. Prostate (1990) 1.17
Persistent membrane translocation of protein kinase C alpha during 12-0-tetradecanoylphorbol-13-acetate-induced apoptosis of LNCaP human prostate cancer cells. Cell Growth Differ (1996) 1.17
Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol (1999) 1.16
Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res (1996) 1.16
Nuclear structure and the three-dimensional organization of DNA. J Cell Biochem (1991) 1.16
Vitamin E inhibits the high-fat diet promoted growth of established human prostate LNCaP tumors in nude mice. J Urol (1999) 1.14
Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587). Clin Cancer Res (1998) 1.12
Programmed death of nonproliferating androgen-independent prostatic cancer cells. Cancer Res (1991) 1.12
A novel M(r) 32,000 nuclear phosphoprotein is selectively expressed in cells competent for self-renewal. Cancer Res (1993) 1.12
Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res (1995) 1.11
Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate (1989) 1.11
Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Res (1999) 1.11